Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy predominantly affecting older adults. Despite the advancements in new therapies for AML, older and medically unfit patients continue to suffer from poor outcomes due to disease-related factors such as the mutational profile and patient-related factors such as comorbidities and performance status. In this review, we discuss a spectrum of therapeutic options for older patients with AML starting with a historical perspective and ending with therapies being investigated in clinical trials. We review the standard of care treatment options including combination venetoclax and hypomethylating agents, in addition to targeted therapies such as FLT3 and IDH inhibitors. Lastly, we shed light on challenges facing the care of older adults and their representation in clinical trials.
急性髓系白血病（AML）是一种侵袭性髓系恶性肿瘤，主要影响老年人群。尽管AML新疗法已取得进展，但由于疾病相关因素（如突变谱）和患者相关因素（如合并症与体能状态）的影响，老年及体弱患者仍面临不良预后。本文综述了老年AML患者的治疗策略，从历史视角出发，延伸至临床试验中的新兴疗法。我们系统回顾了标准治疗方案，包括维奈托克联合去甲基化药物的应用，以及FLT3抑制剂、IDH抑制剂等靶向治疗。最后，我们探讨了老年AML患者临床管理面临的挑战及其在临床试验中的代表性问题。
肿瘤(癌症)患者之家